ADHD Psychiatrist: What They Do, Wait Times and Who Prescribes

An ADHD psychiatrist is a physician specializing in mental health who evaluates, diagnoses and treats attention-deficit/hyperactivity disorder, including prescribing and adjusting medication. A psychiatrist is one of several clinicians who can make the diagnosis: CDC lists psychologists, psychiatrists and primary care providers such as pediatricians^[6].

Most children's ADHD prescriptions do not come from psychiatrists. In 2023, pediatricians accounted for about 11.7 million filled ADHD prescriptions for children, compared with about 6.1 million from psychiatrists^[1]. Prevalence figures for ADHD are on the condition page.

A psychiatrist's role is clearest in complex cases. The American Academy of Pediatrics (AAP) guideline says a primary care clinician who finds possible co-occurring conditions and is not trained or experienced in diagnosing or treating them should refer the patient to an appropriate subspecialist^[7].

The work of an ADHD psychiatrist typically covers:

• A diagnostic evaluation against DSM-5 criteria, including ruling out conditions that mimic ADHD
• Starting, dosing and switching stimulant or nonstimulant medication
• Diagnosing and treating co-occurring anxiety, depression, substance use and other conditions
• Coordinating with therapists, schools and primary care

No. Under the 2019 AAP guideline, a pediatrician or other primary care clinician should start an ADHD evaluation for any child or adolescent from age 4 to the 18th birthday who has academic or behavioral problems plus symptoms of inattention, hyperactivity or impulsivity^[7].

For adults, CDC likewise lists primary care providers alongside psychologists and psychiatrists as clinicians who can diagnose ADHD^[6]. Psychologists diagnose and provide behavioral treatment; prescribing authority varies by profession and state, which the kinds of therapists guide covers.

Referral to a psychiatrist is more likely when the picture is complicated. The AAP guideline asks clinicians to at least screen for emotional and behavioral conditions such as anxiety, depression, oppositional defiant disorder and substance use, developmental conditions such as learning disorders and autism, and physical conditions such as tics and sleep apnea^[7].

Those overlaps are common. Nearly 78% of children with ADHD had at least one co-occurring condition, and about 4 in 10 had anxiety^[8].

There is no single test for ADHD, and sleep disorders, anxiety, depression and some learning disabilities can produce similar symptoms^[6]. An evaluation therefore combines a symptom history, information from other people and a check for look-alike conditions.

The clinician compares symptoms with DSM-5 criteria. DSM-5 lowered the minimum from six to five symptoms in either domain (inattention or hyperactivity-impulsivity) for older adolescents and adults, and requires symptoms to begin before age 12 and appear in two or more settings^[9].

For children, the AAP recommends documenting symptoms and impairment in more than one major setting, drawing on reports from parents or guardians, teachers and other school staff^[7]. For adults, the onset-before-12 criterion means the evaluation looks back at childhood as well as current functioning^[9].

Because there is no lab or imaging test, the visit is mostly interview and questionnaires. The ADHD test guide covers the screening tools and rating scales used.

Prescribing has shifted toward nurse practitioners (NPs) and physician assistants (PAs). Using IQVIA data covering 95% of prescriptions filled in U.S. retail and mail-order pharmacies, researchers found NPs and PAs accounted for 32.1% of filled stimulant prescriptions in 2023, up from 20.7% in 2019^[1].

Their share of nonstimulant fills rose faster, from 27.7% to 42.7% over the same years^[1]. Overall, NPs and PAs wrote about one in three ADHD medication fills in 2023^[1].

Psychiatrists lean more on nonstimulants than pediatricians do. In 2023, 26.9% of psychiatrists' ADHD medication fills for children were nonstimulants, compared with 12.0% of pediatricians' fills^[1]. The data count fills, not reasons, so they cannot show why the patterns differ.

Stimulant fills rose 20.4% between 2019 and 2023, while nonstimulant fills rose 60.1%^[1]. Drug classes and trial results are covered in ADHD meds; dispensing trends are in ADHD medication statistics.

Access is the main practical barrier. In a secret-shopper study that called 948 psychiatrists in New York, California, North Dakota, Virginia and Wyoming from May to July 2022, 18.5% were available to see new patients^[2].

The median wait was 67 days for an in-person appointment and 43 days for telepsychiatry^[2]. The study covered general psychiatry rather than ADHD clinics, and five states may not represent the whole country.

Workforce projections point the same way. HRSA counted 52,164 psychiatrists in 2023 and, under its status quo scenario, projects 2038 adequacy of 50% for adult psychiatrists and 61% for child and adolescent psychiatrists^[3].

Psychiatric nurse practitioners are the exception, with a projected surplus of 2,940 in the same scenario^[3]. That is consistent with the prescribing shift toward NPs. Broader shortage data are in mental health workforce shortage.

Yes, for now. DEA and HHS have extended pandemic-era rules that let a DEA-registered practitioner prescribe Schedule II–V controlled substances by telemedicine without an in-person evaluation, through December 31, 2026^[4]. ADHD stimulants are controlled medications, so the rule governs online ADHD prescribing.

The January 2026 extension is the fourth; HHS said more than 7 million controlled-medication prescriptions were issued via telemedicine without a prior in-person visit in 2024^[10]. A permanent framework, including a proposed special registration for telemedicine, was still pending when the extension was announced^[10].

Adults with ADHD use these channels heavily. In a late-2023 national survey, 46.0% of adults with current ADHD had ever received telehealth services for the condition, and 30.5% had used telehealth to get an ADHD prescription since March 2020^[5].

A prescription does not guarantee a filled one. Among adults taking a stimulant, 71.5% reported difficulty filling it in the previous 12 months because the medication was unavailable^[5].

About 6.0% of U.S. adults reported a current ADHD diagnosis in October–November 2023, and 55.9% of them were diagnosed at age 18 or older^[5]. Adult prevalence data are on the adults with ADHD page.

Treatment is uneven. In the same survey, 36.5% of adults with ADHD were receiving no treatment, 35.2% were receiving both medication and counseling or behavioral treatment, and 50.4% had been prescribed ADHD medication in the previous 12 months^[5].

Prescription data show the same tilt toward adults. Nonstimulant fills rose 172.9% among adults 31 and older between 2019 and 2023, versus 24.1% among children^[1].

How treatment options compare by age is covered in treating ADHD; children's data are on the children with ADHD page.